Pfizer Extends Contract with OGS into Fourth Year
Pfizer has agreed to renew its research contract with Oxford GlycoSciences for a fourth year, OGS said last week.
Oxford, UK-based OGS will continue to pursue its proteomics discovery research in the areas of Alzheimers disease and atherosclerosis, in return for about $5 million a year in fees, said OGS COO Stephen Parker.
Pfizer is pretty hard-headed, so they must have believed that theres still more value [in the collaboration], Parker said.
Parker said the two companies have filed for patents on previous discoveries, and that while Pfizer has rights to potential pharmaceuticals resulting from the research, OGS retains the right to use its discoveries as diagnostics.
Pfizer took a $2.5 million equity stake in OGS when the two parties first began collaborating in 1998.
Millipore, Proteome Systems Launch In-Gel Digest Kits
Proteome Systems and Millipore have released the Millipore Montage In-Gel Digest kits, the companies said last week. The product is the first from their collaboration announced earlier this year.
The kits allow multiple gel samples to be prepared simultaneously for mass spectrometry analysis, and include a low binding 96-well filtration plate, as well as the enzymes, reagents, and disposables necessary for digesting up to 96 protein samples from 1D or 2D electrophoresis gels. For improved mass spectrometry data quality, one type of the kits also includes ZipTip pipette tips for concentrating and desalting samples.
Bruker AXS IPO Brings in $53M for X-ray Developer
Bruker AXS earned $53 million after filing an initial public offering on Dec. 14 that let loose 9 million shares of common stock at a cost of $6.50 apiece. Shares of the Madison, Wis.-based firm began trading on the Nasdaq under the ticker symbol BAXS.
In spite of the windfall, Bruker AXS had expected to garner between $8 and $10 per share, according to earlier reports.
The company said it plans to use the proceeds for general purposes, including R&D, expanding sales and marketing, strategic acquisitions, general expansion, and debt repayment.
Bruker AXS develops and sells advanced systems for x-ray crystallography, x-ray diffraction, and x-ray fluorescence analysis.
Former Genencor Exec Joins IPI as VP for Antibacterials
Integrative Proteomics (IPI) of Toronto has appointed Molly Schmid senior vice president for antibacterial pharmaceuticals and alliances, the company said last week.
Prior to joining IPI, Schmid served as senior director for functional genomics and bioinformatics at Genencor. In previous positions, she served as vice president for research alliances at Microcide Pharmaceuticals, and as an assistant professor of molecular biology at Princeton University.
Dr. Schmids previous industry experience, along with her pioneering work on using genetic and genomic methods for antimicrobial drug discovery, make her an ideal leader for IPIs ongoing antibacterial program, said John Mendlein, IPIs chairman and CEO.